Back to News
Market Impact: 0.25
Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Addex Therapeutics said its spin-out Neurosterix completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia. The announcement reports a development milestone but provides no trial results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ADXN0.45
More News
- Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- Guitar Center is dropping its ban on playing ‘Stairway to Heaven.’ It’s part of the CEO’s big turnaround plan
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit